What are the most common mistakes with MT-1 (Melanotan I)?
The most common MT-1 (Melanotan I) mistakes are skipping the mole-map baseline; no UV exposure during the cycle (no pigment response); confusing dosing protocol with MT-2. Most issues people run into come down to protocol and expectations, not the compound itself. Going in informed matters here because human evidence for MT-1 (Melanotan I) is limited.
Common MT-1 (Melanotan I) mistakes
- Skipping the mole-map baseline
- No UV exposure during the cycle (no pigment response)
- Confusing dosing protocol with MT-2
References
- Afamelanotide for Erythropoietic Protoporphyria (Scenesse approval data) — Langendonk JG et al., NEJM, 2015
- Skin pigmentation and pharmacokinetics of melanotan-I in humans — Ugwu SO, Blanchard J, Dorr RT, Levine N, et al.; Biopharmaceutics & Drug Disposition; 1997
- Afamelanotide: An Orphan Drug with Potential for Broad Dermatologic Applications — Wu J, Cotliar R; Journal of Drugs in Dermatology; 2021
Pepdex is an editorial reference, not medical advice. Peptides vary in legal and approval status by country, many are research compounds without full human safety data. Talk to a qualified clinician before starting anything.
More on MT-1 (Melanotan I)
Full MT-1 (Melanotan I) breakdownMT-1 (Melanotan I) what it's used forMT-1 (Melanotan I) side effectsMT-1 (Melanotan I) how to take itMT-1 (Melanotan I) who should avoid itMT-1 (Melanotan I) half-lifeMT-1 (Melanotan I) how long to workMT-1 (Melanotan I) legal statusMT-1 (Melanotan I) how it worksmt 1 vs mt 2Ask the AI Coach
Last updated 2026-06-15.